Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis

NAPLES, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for zamubafusp alfa (AT-02) for the treatment of light chain (AL) amyloidosis, a rare, progressive, debilitating, and often fatal condition.

Zamubafusp alfa, the company’s lead pan-amyloid removal candidate, has been evaluated in a completed Phase 1 study and is currently being studied in an ongoing Phase 2 open-label trial, both of which enrolled patients with AL amyloidosis.